Cart
sales@molnova.com
BPR1J-097 hydrochloride
CAS No. ——
BPR1J-097 hydrochloride ( —— )
Catalog No. M17703 CAS No. ——
BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 94 | Get Quote |
|
| 10MG | 154 | Get Quote |
|
| 50MG | 473 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBPR1J-097 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionBPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
-
DescriptionBPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorFLT3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight553.07
-
Molecular FormulaC27H29ClN6O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)C4=CC(=CC=C4)NS(=O)(=O)C5=CC=CC=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lin WH, et al. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br J Cancer. 2012 Jan 31;106(3):475-81.
molnova catalog
related products
-
740 Y-P(TFA)
740 Y-P(TFA) is a potent and cell-permeable activator of PI3K.740 Y-P is a synthetic biotinylated peptide.
-
iMDK
iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.
-
Tibolone
Tibolone is an estrogen-like compound used for the treatment of the symptoms associated with menopausal transition (i.e., climacteric symptoms) and also for the treatment of osteoporosis.
